tirzepatide molecule structure (LY3298176) sodium | GIP/GLP-1 Receptor Agonist | CAS 2023788-19-2 (free base) RCSB PDB - 7FIM: Cryo-EM
Description
Guidelines: 2021 ESC Cardiovascular Prevention Question #31 with Dr
Study participants were insulin-nave and had a mean duration of diabetes of 8.4 years, a baseline A1C of 8.17% and a baseline weight of 94.3 kg
The FDA requires cardiovascular outcomes trial data for weight loss drugs
It is a receptor agonist and should not replace insulin therapy in individuals who require it
